5 November 2022
Latham & Watkins Advises on Kura Oncology’s Financing Agreement
Advising firms
Deal team
10 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Haim Zaltzman Lead | Latham & Watkins LLP | Partner | transactional | Bay Area |
| Dan Van Fleet Lead | Latham & Watkins LLP | Partner | transactional | Bay Area |
| Jim Morrone Lead | Latham & Watkins LLP | Partner | transactional | Bay Area |
| Erin Cusenbary | Latham & Watkins LLP | Associate | transactional | Austin |
| Cooper Shear | Latham & Watkins LLP | Associate | transactional | Austin |
| Eric Cho | Latham & Watkins LLP | Partner | tax | Los Angeles |
| Chad Jennings | Latham & Watkins LLP | Associate | regulatory | Washington, D.C. |
| Reza Mojtabaee-Zamani | Latham & Watkins LLP | Partner | corporate | New York |
| Eric Rice | Latham & Watkins LLP | Associate | corporate | New York |
| Erica Kucharski | Latham & Watkins LLP | Associate | corporate | Chicago |
Stated terms
- Stated value
- USD 125m (US$125 million)
- What the figure measures
- Facility amount
- Client
- Hercules Capital, Inc.Lenders
- Counterparties
- Kura Oncology, Inc. (Borrower)
Bristol Myers Squibb (Investor)